<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940705-2-00225</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;V&hyph;F. The RAC Chair will provide a report on all human gene  <!-- PJG 0012 frnewline --> transfer protocols that have been approved by NIH/ORDA at the next regularly  <!-- PJG 0012 frnewline --> scheduled RAC meeting.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;V&hyph;F&hyph;1. In accordance with Reporting Requirements (See Appendix M&hyph; IV), any adverse effects of the treatment should be reported immediately to the local Institutional Review Board, the NIH Office for Protection from Research Risks, and NIH/ORDA followed by the submission of a written report filed with each group. Reports submitted to NIH/ORDA shall be sent to the Office of Recombinant DNA Activities, National Institutes of Health, Building 31, Room 4B11, Bethesda, Maryland 20892, (301) 496&hyph;9838.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;V&hyph;F&hyph;2. In accordance with Reporting Requirements (see Appendix M&hyph; IV), reports regarding the general progress of patients should be filed with both the local Institutional Review Board and NIH/ORDA within six months of the commencement of the experiment and at six-month intervals thereafter. In the event of a patient's death, a summary of the special post-mortem studies and statement of the cause of death should be submitted to the Institutional Review Board and NIH/ORDA, if available.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI. Procedures to be Followed for Expedited Review of Single Patient Human Gene Transfer Experiments by NIH Director Under Section III&hyph;A&hyph;2  <!-- PJG 0012 frnewline --> Requests for Expedited Review should be submitted to the Office of Recombinant  <!-- PJG 0012 frnewline --> DNA Activities, National Insitutes of Health, Bethesda, Maryland 20892, (301)  <!-- PJG 0012 frnewline --> 496&hyph;9838.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;A. A Principal Investigator submitting a request to the  <!-- PJG 0012 frnewline --> NIH/ORDA for Expedited Review of a single patient gene transfer protocol shall  <!-- PJG 0012 frnewline --> provide detailed information regarding the necessity of Expedited Review.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;B. No protocol shall be considered without relevant Institutional Biosafety Committee and Institutional Review Board approvals.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;C. At this time, all gene transfer protocols are considered  <!-- PJG 0012 frnewline --> experimental.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;D. Regardless of the method of review, the Points to Consider is the standard of review for all gene transfer protocols.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;E. Review of such protocols may include intramural NIH experts but must include extramural experts.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;F. The reviewers shall consider similarity of the new protocol to previously approved protocols.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;G. The NIH/ORDA shall report to the RAC following Expedited  <!-- PJG 0012 frnewline --> Review and include all of the materials on which the decision was based. The  <!-- PJG 0012 frnewline --> RAC shall formally review the protocol at its next scheduled meeting. Patient  <!-- PJG 0012 frnewline --> privacy shall be maintained.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;H. Protocols that are deferred or not approved by the RAC in its normal review process are not eligible for Expedited Review. No protocol shall have more than one patient approved under Expedited Review.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;I. As requested in the context of non-expedited review, none of the costs of the experimental protocol shall be borne by the patient or the patient's family.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Appendix M&hyph;VI&hyph;J. Data on all patients undergoing gene transfer shall be provided to the RAC within six months of the procedure.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> Appendix M&hyph;VII. Footnotes of Appendix M  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Appendix M&hyph;VII&hyph;A. The Food and Drug Administration has jurisdiction over  <!-- PJG 0012 frnewline --> products intended for use in human gene transfer clinical trials. For general  <!-- PJG 0012 frnewline --> information on the Food and Drug Administration's policies and regulatory  <!-- PJG 0012 frnewline --> requirements, see the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , Volume 51, pages 23309&hyph;23313, 1986.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            